The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Inflammatory Biomarkers and Exacerbations in Chronic Obstructive Pulmonary Disease
Abstract
Importance: Exacerbations of respiratory symptoms in chronic obstructive pulmonary disease (COPD) have profound and long-lasting adverse effects on patients. Objective: To test the hypothesis that elevated levels of inflammatory biomarkers in individualswith stableCOPDare associated with an increased risk of having exacerbations. Design, Setting, and Participants: Prospective cohort study examining 61 650 participants with spirometry measurements from the Copenhagen City Heart Study (2001-2003) and the Copenhagen General Population Study (2003-2008). Of these, 6574 had COPD, defined as a ratio between forced expiratory volume in 1 second (FEV1) and forced vital capacity below 0.7. Main Outcomes and Measures: Baseline levels of C-reactive protein (CRP) and fibrinogen and leukocyte count were measured in participants at a time when they were not experiencing symptoms of exacerbations. Exacerbations were recorded and defined as short-course treatment with oral corticosteroids alone or in combination with an antibiotic or as a hospital admission due to COPD. Levels of CRP and fibrinogen and leukocyte countwere defined as high or low according to cut points of 3 mg/L, 14 μmol/L, and 9 × 109/L, respectively. Results: During follow-up, 3083 exacerbations were recorded (mean, 0.5/participant). In the first year of follow-up, multivariable-adjusted odds ratios for having frequent exacerbations were 1.2 (95% CI, 0.7-2.2; 17 events/1000 person-years) for individuals with 1 high biomarker, 1.7 (95% CI, 0.9-3.2; 32 events/1000 person-years) for individuals with 2 high biomarkers, and 3.7 (95% CI, 1.9-7.4; 81 events/1000 person-years) for individuals with 3 high biomarkers compared with individuals who had no elevated biomarkers (9 events/1000 person-years; trend: P =2 × 10-5). Corresponding hazard ratios using maximum follow-up time were 1.4 (95% CI, 1.1-1.8), 1.6 (95% CI, 1.3-2.2), and 2.5 (95% CI, 1.8-3.4), respectively (trend: P =1 × 10-8). The addition of inflammatory biomarkers to a basic model including age, sex, FEV1 percent predicted, smoking, use of any inhaled medication, body mass index, history of previous exacerbations, and time since most recent prior exacerbation improved the C statistics from 0.71 to 0.73 (comparison: P =9 × 10-5). Relative risks were consistent in those with milder COPD, in those with no history of frequent exacerbations, and in the 2 studies separately. The highest 5-year absolute risks of having frequent exacerbations in those with 3 high biomarkers (vs no high biomarkers) were 62% (vs 24%) for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n=558), 98% (vs 64%) in those with a history of frequent exacerbations (n=127), and 52% (vs 15%) for those with GOLD grades 3-4 (n=465). Conclusions and Relevance: Simultaneously elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations. Further investigation is needed to determine the clinical value of these biomarkers for risk stratification. ©2013 American Medical Association. All rights reserved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationPencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“FEV1 percent predicted, median (IQR) 80 (67-92) 82 (70-93) 44 (39-48) 80 (67-92) 69 (48-85) 82 (70-93) 43 (37-47) BMI, median (IQR)c 25 (23-28) 25 (23-28) 25 (22-28) 25 (23-28) 25 (23-28) 25 (23-28) 25 (22-28)”
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Self-citationEffect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Donaldson, G. C. (2002) · Thorax · doi:10.1136/thorax.57.10.847 · Cited by 2,272
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
Gan, W. Q. (2004) · Thorax · doi:10.1136/thx.2003.019588 · Cited by 1,838
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Connors, A. F., Dawson, N. V., Thomas, C., Harrell, F. E., Desbiens, N., Fulkerson, W. J., Kussin, P., Bellamy, P., Goldman, L., & Knaus, W. A. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.4.8887592 · Cited by 1,393
Greenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease
Sethi, S., & Murphy, T. F. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800353 · Cited by 1,234
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Agustí, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R., Miller, B. E., Vestbo, J., Lomas, D. A., Calverley, P. M. A., Wouters, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037483 · Cited by 848
Self-citationGenetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationSeneff, M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530230038027 · Cited by 593
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Dahl, M., Vestbo, J., Lange, P., Bojesen, S. E., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-713oc · Cited by 543
Self-citationInterpreting Incremental Value of Markers Added to Risk Prediction Models
Pencina, M. J., D'Agostino, R. B., Pencina, K. M., Janssens, A. C. J. W., & Greenland, P. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws207 · Cited by 506
Pulmonary Arterial Enlargement and Acute Exacerbations of COPD
Wells, J. M., Washko, G. R., Han, M. K., Abbas, N., Nath, H., Mamary, A. J., Regan, E., Bailey, W. C., Martinez, F. J., Westfall, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203830 · Cited by 499
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Exacerbations of chronic obstructive pulmonary disease
Celli, B. R., & Barnes, P. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00109906 · Cited by 462
Seemungal, T., MacCallum, P., Paul, E., Donaldson, G., Bhowmik, A., Jeffries, D., Meade, T., & Wedzicha, J. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613998 · Cited by 447
Celli, B. R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B. E., Bakke, P., Calverley, P., Coxson, H., Crim, C., Edwards, L. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1792oc · Cited by 432
Self-citationMallia, P., Message, S. D., Gielen, V., Contoli, M., Gray, K., Kebadze, T., Aniscenko, J., Laza-Stanca, V., Edwards, M. R., Slater, L., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0833oc · Cited by 415
Lange, P., Marott, J. L., Vestbo, J., Olsen, K. R., Ingebrigtsen, T. S., Dahl, M., & Nordestgaard, B. G. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1299oc · Cited by 362
Self-citationDAHL, M., TYBJŒRG-HANSEN, A., VESTBO, J., LANGE, P., & NORDESTGAARD, B. G. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2010067 · Cited by 260
Self-citationPatient Understanding, Detection, and Experience of COPD Exacerbations
Kessler, R., Ståhl, E., Vogelmeier, C., Haughney, J., Trudeau, E., Löfdahl, C.-G., & Partridge, M. R. (2006) · Chest · doi:10.1378/chest.130.1.133 · Cited by 255
Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease
Thomsen, M., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1113oc · Cited by 245
Self-citationFactor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population
Juul, K., Tybjærg-Hansen, A., Schnohr, P., & Nordestgaard, B. G. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00008 · Cited by 195
Self-citationEffect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD
Powrie, D. J., Wilkinson, T. M. A., Donaldson, G. C., Jones, P., Scrine, K., Viel, K., Kesten, S., & Wedzicha, J. A. (2007) · European Respiratory Journal · doi:10.1183/09031936.00023907 · Cited by 178
COPD association and repeatability of blood biomarkers in the ECLIPSE cohort
Dickens, J. A., Miller, B. E., Edwards, L. D., Silverman, E. K., Lomas, D. A., Tal-Singer, R., & the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators (2011) · Respiratory Research · doi:10.1186/1465-9921-12-146 · Cited by 168
Dentener, M. A. (2001) · Thorax · doi:10.1136/thorax.56.9.721 · Cited by 165
Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations
Groenewegen, K. H., Postma, D. S., Hop, W. C. J., Wielders, P. L. M. L., Schlösser, N. J. J., & Wouters, E. F. M. (2008) · Chest · doi:10.1378/chest.07-1342 · Cited by 160
Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry
Thomsen, R. W., Lange, P., Hellquist, B., Hansen, E. F., Bartels, P. D., Krog, B. R., Hansen, A.-M. S., Buck, D., & Bunk, A. E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.01.012 · Cited by 157
Self-citationRole of Latent Viral Infections in Chronic Obstructive Pulmonary Disease and Asthma
Hogg, J. C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.supplement_2.2106063 · Cited by 155
Emerging anti-inflammatory strategies for COPD
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · European Respiratory Journal · doi:10.1183/09031936.00213711 · Cited by 109
C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach
Dahl, M., Vestbo, J., Zacho, J., Lange, P., Tybjærg–Hansen, A., & Nordestgaard, B. G. (2010) · Thorax · doi:10.1136/thx.2009.131193 · Cited by 88
Self-citation
Cited by
Vedel-Krogh, S., Nielsen, S. F., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201509-1869oc · Cited by 431
Self-citationCOPD and its comorbidities: Impact, measurement and mechanisms
Negewo, N. A., Gibson, P. G., & McDonald, V. M. (2015) · Respirology · doi:10.1111/resp.12642 · Cited by 311
The Healthy Immigrant Effect and Aging in the United States and Other Western Countries
Markides, K. S., & Rote, S. (2019) · The Gerontologist · doi:10.1093/geront/gny136 · Cited by 283
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease
Rennard, S. I., Dale, D. C., Donohue, J. F., Kanniess, F., Magnussen, H., Sutherland, E. R., Watz, H., Lu, S., Stryszak, P., Rosenberg, E., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0992oc · Cited by 261
Frailty phenotypes and mortality after lung transplantation: a prospective cohort study
Singer, J. P., Diamond, J. M., Anderson, M. R., Katz, P. P., Covinsky, K., Oyster, M., Blue, T., Soong, A., Kalman, L., Shrestha, P., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14873 · Cited by 133
Metadata
- Authors
- Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-12
- Volume
- 309
- Issue
- 22
- Pages
- 2353
- ISSN
- 0098-7484
- OpenAlex
- W2069875525
- Cited by
- 401
- References
- 38
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.